Back to search
FDAFDA · Food and drugs·Recall number D-0641-2020

Glenmark Ranitidine Tablets USP 300 mg Rx Only 30 Tablets Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bandez, Goa 403513, India Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ NDC 68462-249-30

Published January 15, 2020 · Recall initiated: December 17, 2019

Summary

FDA records drug Class II recall D-0641-2020, published January 15, 2020 and initiated December 17, 2019. Recalling firm: Glenmark Pharmaceuticals Inc., USA; Status: Ongoing; Reported quantity: 98,988 bottles; Lot: 7701429A 7701522A 7702255A 7704745A 19190456 19190472 19190490. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Presence of NDMA impurity detected in product.

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Glenmark Pharmaceuticals Inc., USA
Distributor
Natiowide
Lot
7701429A 7701522A 7702255A 7704745A 19190456 19190472 19190490
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Glenmark Ranitidine Tablets USP 300 mg Rx Only 30 Tablets Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bandez, Goa 403513, India Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ NDC 68462-249-30 recalled?

Yes. FDA published recall D-0641-2020 on January 15, 2020. Reported hazard: CGMP Deviations: Presence of NDMA impurity detected in product.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release